Pater Cornel
Hanover, Germany.
Curr Control Trials Cardiovasc Med. 2004 Aug 16;5(1):7. doi: 10.1186/1468-6708-5-7.
Adjusting drug therapy to the individual, a common approach in clinical practice, has evolved from 1) dose adjustments based on clinical effects to 2) dose adjustments made in response to drug levels and, more recently, to 3) dose adjustments based on deoxyribonucleic acid (DNA) sequencing of drug-metabolizing enzyme genes, suggesting a slow drug metabolism phenotype. This development dates back to the middle of the 20(th )century, when several different drugs were administered on the basis of individual plasma concentration measurements. Genetic control of drug metabolism was well established by the 1960s, and pharmakokinetic-based individualized therapy was in use by 1973.
根据个体情况调整药物治疗是临床实践中的常见方法,它已从1)基于临床效果的剂量调整发展到2)根据药物水平进行的剂量调整,以及最近的3)基于药物代谢酶基因的脱氧核糖核酸(DNA)测序进行的剂量调整,提示药物代谢缓慢的表型。这一发展可追溯到20世纪中叶,当时根据个体血浆浓度测量结果使用了几种不同的药物。到20世纪60年代,药物代谢的遗传控制已得到充分确立,到1973年基于药代动力学的个体化治疗开始应用。